66 related articles for article (PubMed ID: 11138684)
1. FDG PET in thyroid cancer: thyroxine or not?
Grünwald F; Biersack HJ
J Nucl Med; 2000 Dec; 41(12):1996-8. PubMed ID: 11138684
[No Abstract] [Full Text] [Related]
2. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.
Moog F; Linke R; Manthey N; Tiling R; Knesewitsch P; Tatsch K; Hahn K
J Nucl Med; 2000 Dec; 41(12):1989-95. PubMed ID: 11138683
[TBL] [Abstract][Full Text] [Related]
3. Clinical usefulness of FDG PET in differentiated thyroid cancer.
Macapinlac HA
J Nucl Med; 2001 Jan; 42(1):77-8. PubMed ID: 11197984
[No Abstract] [Full Text] [Related]
4. Changing paradigms in the follow-up of patients with differentiated thyroid cancer: an alternative to [18F]fluorodeoxyglucose positron emission tomographic scanning.
Mazzaferri EL
Endocr Pract; 2003; 9(4):324-6. PubMed ID: 14561580
[No Abstract] [Full Text] [Related]
5. Usefulness of 18F-FDG PET/CT in thyroid carcinoma.
Muros de Fuentes MA; Mitjavila Casanovas M; Estorch Cabrera M; Lecumberri Santamaria B; Navarro González E
Rev Esp Med Nucl Imagen Mol; 2016; 35(3):186-92. PubMed ID: 26944558
[No Abstract] [Full Text] [Related]
6. Increased F-18 fluorodeoxyglucose accumulation in a benign neurofibroma--a pitfall in a patient with thyroid cancer: a case report.
Gabriel M; Erler H; Donnemiller E; Riccabona G
Nuklearmedizin; 2002 Apr; 41(2):N14-5. PubMed ID: 11989305
[No Abstract] [Full Text] [Related]
7. Role of FDG PET in metastatic thyroid cancer.
Wong CO; Dworkin HJ
J Nucl Med; 1999 Jun; 40(6):993-4. PubMed ID: 10452316
[No Abstract] [Full Text] [Related]
8. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
9. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in cancer of the thyroid].
Bourguet P;
Bull Cancer; 2003 Feb; 90 Spec No():S105-9. PubMed ID: 12739343
[No Abstract] [Full Text] [Related]
10. [F-18-FDG PET in autonomous goiter].
Börner AR; Voth E; Wienhard K; Wagner R; Schicha H
Nuklearmedizin; 1999; 38(1):1-6. PubMed ID: 9987775
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
12. [Rapid diagnosis of recurrence of a tall cell variant of papillary thyroid cancer by endogenous TSH stimulation].
Görges R; Liedke MO; Worm K; Frilling A; Bockisch A; Schmid KW
Nuklearmedizin; 2003 Jun; 42(3):N15-8. PubMed ID: 12848153
[No Abstract] [Full Text] [Related]
13. Vocal cord muscle activity as a drawback to FDG-PET in the followup of differentiated thyroid cancer.
Igerc I; Kumnig G; Heinisch M; Kresnik E; Mikosch P; Gallowitsch HJ; Gasser J; Haselbach H; Lind P
Thyroid; 2002 Jan; 12(1):87-9. PubMed ID: 11838737
[No Abstract] [Full Text] [Related]
14. The role of F-18FDG PET in thyroid cancer.
Lind P; Kumnig G; Matschnig S; Heinisch M; Gallowitsch HJ; Mikosch P; Kresnik E; Gomez I; Unterweger O
Acta Med Austriaca; 2000; 27(2):38-41. PubMed ID: 10812462
[TBL] [Abstract][Full Text] [Related]
15. Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer.
Feine U
Eur J Endocrinol; 1998 May; 138(5):492-6. PubMed ID: 9625358
[No Abstract] [Full Text] [Related]
16. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.
Wang W; Larson SM; Fazzari M; Tickoo SK; Kolbert K; Sgouros G; Yeung H; Macapinlac H; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 2000 Mar; 85(3):1107-13. PubMed ID: 10720047
[TBL] [Abstract][Full Text] [Related]
18. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.
Alnafisi NS; Driedger AA; Coates G; Moote DJ; Raphael SJ
J Nucl Med; 2000 Jun; 41(6):1010-5. PubMed ID: 10855626
[TBL] [Abstract][Full Text] [Related]
19. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
Schlüter B; Bohuslavizki KH; Beyer W; Plotkin M; Buchert R; Clausen M
J Nucl Med; 2001 Jan; 42(1):71-6. PubMed ID: 11197983
[TBL] [Abstract][Full Text] [Related]
20. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
